Nov 26, 2025

  • Pharmaceuticals
  • R&D

Renalys Pharma’s Announcement Regarding Sparsentan (Results of Domestic Phase III Study for IgA Nephropathy)

TOKYO, November 26, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Renalys Pharma, Inc. (hereinafter “Renalys Pharma”), which Chugai is scheduled to acquire as a wholly-owned subsidiary on November 27, 2025, issued a news release today regarding topline results of the domestic Phase III clinical study for sparsentan for Japanese patients with IgA nephropathy.

Please refer to the link below for details of the news release:
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
https://renalys.com/news/

[PDF 100KB]

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp

Back